Cargando…

Decitabine in patients with myelodysplastic syndromes: A multi‐center, open‐label, dose comparison trial

BACKGROUND: The hypomethylating agent decitabine is the standard therapy for intermediate or high risk myelodysplastic syndrome (MDS). METHODS: In this trial, 191 adult patients with intermediate/high risk MDS (IPSS score ≥ 0.5) randomly received decitabine using a standard regimen (20 mg/m(2)/day f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Hui, Jiang, Hao, Tong, Hongyan, Xia, Ruixiang, Yang, Linhua, Zhao, Hongguo, Ouyang, Jian, Bai, Hai, Sun, Hui, Hou, Li, Jiang, Ming, Zeng, Yun, Liu, Zhuogang, Liang, Aibin, Xie, Yinghua, Yu, Kang, Zhai, Zhimin, Liu, Li, Jia, Jinsong, Fu, Rong, Shao, Zonghong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLE
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358210/ https://www.ncbi.nlm.nih.gov/pubmed/37350499 http://dx.doi.org/10.1002/cam4.5922

Ejemplares similares

Decitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b Study
por: Wu, Depei, et al.
Publicado: (2015)

Effects of decitabine on megakaryocyte maturation in patients with myelodysplastic syndromes
por: DING, KAI, et al.
Publicado: (2016)

Decitabine in the treatment of myelodysplastic syndromes
por: Saba, Hussain I
Publicado: (2007)

Clinical effect of decitabine in the treatment of myelodysplastic syndrome and influencing factors
por: Liu, Tangxia, et al.
Publicado: (2020)

Mechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome
por: Qin, Taichun, et al.
Publicado: (2011)

Spotlight on decitabine for myelodysplastic syndromes in Chinese patients
por: Jing, Yu, et al.
Publicado: (2015)

Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study
por: Wang, Lixin, et al.
Publicado: (2020)

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes
por: Garcia, Jacqueline S, et al.
Publicado: (2010)

Decitabine/cedazuridine for chronic myelomonocytic leukaemia, myelodysplastic syndromes
Publicado: (2022)

Gut Microbiome and Plasma Metabolomic Analysis in Patients with Myelodysplastic Syndrome
por: Jiang, Huijuan, et al.
Publicado: (2022)

Abnormal Ferroptosis in Myelodysplastic Syndrome
por: Lv, Qi, et al.
Publicado: (2020)

Effective treatment of low-dose decitabine in myelodysplastic syndrome/myeloproliferative neoplasms
por: Ye, Xingnong, et al.
Publicado: (2017)

Gene Expression Profiles Identify Biomarkers of Resistance to Decitabine in Myelodysplastic Syndromes
por: Kim, Seungyoun, et al.
Publicado: (2021)

Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada
por: Yun, John Paul, et al.
Publicado: (2023)

Decitabine of Reduced Dosage in Chinese Patients with Myelodysplastic Syndrome: A Retrospective Analysis
por: Li, Xiao, et al.
Publicado: (2014)

Elevated TWIST1 expression in myelodysplastic syndromes/ acute myeloid leukemia reduces efficacy of hypomethylating therapy with decitabine
por: Li, Hongjiao, et al.
Publicado: (2020)

Monocyte-Derived Macrophages Are Impaired in Myelodysplastic Syndrome
por: Han, Yu, et al.
Publicado: (2016)

P741: PATIENTS’ PERSPECTIVES ON ORAL DECITABINE AND CEDAZURIDINE FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES
por: Zeidan, Amer M., et al.
Publicado: (2023)

Abnormal populations and functions of natural killer cells in patients with myelodysplastic syndromes
por: Zhang, Wei, et al.
Publicado: (2018)

Abnormal changes in the quantity and function of osteoblasts cultured in vitro in patients with myelodysplastic syndrome
por: Gao, Shan, et al.
Publicado: (2018)

Mutations in genes affecting DNA methylation enhances responses to decitabine in patients with myelodysplastic syndrome
por: Jung, Hyun Ae, et al.
Publicado: (2021)

Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study
por: Hu, Naibo, et al.
Publicado: (2021)

Decitabine Induces Change of Biological Traits in Myelodysplastic Syndromes via FOXO1 Activation
por: Zhang, Zheng, et al.
Publicado: (2021)

Impaired Mitophagy of Nucleated Erythroid Cells Leads to Anemia in Patients with Myelodysplastic Syndromes
por: Jiang, Huijuan, et al.
Publicado: (2018)

Altered follicular helper T cell impaired antibody production in a murine model of myelodysplastic syndromes
por: Jiang, Huijuan, et al.
Publicado: (2017)

All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RARα-Nrf2 complex
por: Wang, Lu, et al.
Publicado: (2022)

A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome
por: Jeong, Seong Hyun, et al.
Publicado: (2015)

A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome
por: Almasri, Jehad, et al.
Publicado: (2018)

Single-cell RNA sequencing identifies the properties of myelodysplastic syndrome stem cells
por: Liu, Yumei, et al.
Publicado: (2022)

Decitabine-Induced Changes in Human Myelodysplastic Syndrome Cell Line SKM-1 Are Mediated by FOXO3A Activation
por: Zeng, Wen, et al.
Publicado: (2017)

Abnormal Macrophage Polarization in Patients with Myelodysplastic Syndrome
por: Zhang, Gaochao, et al.
Publicado: (2021)

Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome
por: Han, Seunghoon, et al.
Publicado: (2015)

Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients
por: Jung, Hyun Ae, et al.
Publicado: (2015)

Severe pyoderma gangrenosum caused by myelodysplastic syndrome successfully treated with decitabine administered by a noncytotoxic regimen
por: Saleh, Mostafa F. M., et al.
Publicado: (2017)

Lenalidomide Plus Decitabine Treatment in a Myelodysplastic Syndrome Patient With Deletion 5q and Excess Blasts
por: Serin, Istemi, et al.
Publicado: (2020)

Myeloid-derived suppressor cell cytokine secretion as prognostic factor in myelodysplastic syndromes
por: Han, Dong, et al.
Publicado: (2020)

Increased Circulating of CD54(high)CD181(low) Neutrophils in Myelodysplastic Syndrome
por: Yang, Liyan, et al.
Publicado: (2021)

Allogeneic haematopoietic stem cell transplantation with decitabine-containing preconditioning regimen in TP53-mutant myelodysplastic syndromes: A case study
por: Wang, Yuxin, et al.
Publicado: (2022)

Inhibitory effect and related mechanism of decitabine combined with gemcitabine on proliferation of NK/T cell lymphoma cells
por: Lin, Lanke, et al.
Publicado: (2023)

Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone
por: Ye, Li, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_eh39it4ca83m7g0qdcptn69rg4